IMMUNE THROMBOCYTOPENIA
Clinical trials for IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Japanese ITP patients continue experimental drug in extended safety trial
Disease control OngoingThis study allows Japanese adults with chronic immune thrombocytopenia (ITP) who benefited from rilzabrutinib in a previous trial to continue taking the oral medication. The main goal is to monitor long-term safety and side effects. Only 4 participants who completed the earlier s…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Apr 02, 2026 00:42 UTC
-
Licorice root pill tested to boost platelets in blood disorder
Disease control OngoingThis study is testing whether adding a capsule made from a licorice root extract to a standard high-dose steroid treatment works better for adults newly diagnosed with immune thrombocytopenia (ITP), a condition that causes low platelet counts and bleeding risk. It will compare th…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Shandong University • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Trial for new bleeding disorder pill withdrawn before starting
Disease control TerminatedThis was an early-stage study to test the safety and find the right dose of a new oral drug called HMPL-523 for adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing a risk of bleeding. The study was designed to enroll adults wh…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New pill aims to boost platelets in chronic bleeding disorder
Disease control OngoingThis Phase 3 trial tested whether an oral medication called rilzabrutinib could safely and effectively raise and maintain platelet counts in adults and adolescents with persistent or chronic immune thrombocytopenia (ITP). Participants were randomly assigned to receive either the …
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Principia Biopharma, a Sanofi Company • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC